Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday

Cathie Wood added to Space Exploration Technologies (SPCX) while also expanding positions in Generate Biomedicines (GENB) and Bullish (BLSH). SpaceX is set to join the Nasdaq-100 on Tuesday, which should trigger passive index-tracking buying (net effect expected to be supportive but not a lasting catalyst), with the stock ~19% above its $135 IPO price yet ~30% below its third-day peak. For Bullish, the article highlights continued crypto winter pressure, with shares down 72% since its IPO and digital-asset sales down 35%, even as it announced a $4.2B cash-and-stock deal for Equiniti to support growth.

Analysis

The near-term opportunity is flow-driven, not fundamental. The Nasdaq-100 inclusion can create a short-lived dislocation because forced buyers are price-insensitive, but that support usually weakens fast once the rebalance window closes; the real test is whether the company can keep compounding launches and monetization enough to justify a still-extreme revenue multiple. That makes the stock vulnerable to a classic post-event fade if the market starts pricing it as a passive index constituent rather than a venture-style compounder.

Bullish looks like the weaker risk/reward setup. Crypto-linked revenues remain highly cyclical, while acquisition-led diversification can mask, rather than solve, the core earnings problem if trading volumes stay soft; if the deal is stock-funded, dilution becomes a quiet headwind, and if it is cash-funded, balance-sheet flexibility gets consumed just when the cycle is still weak. The second-order winner is the more institutional, higher-liquidity crypto venue set; the loser is any platform trying to buy growth before the underlying market recovers.

Generate Biomedicines is still a duration asset, not an earnings asset. The market tends to overestimate how much "AI biology" compresses clinical timelines; until there is reproducible human efficacy, the name will trade more like speculative biotech than software, with rate sensitivity and risk appetite dominating. Contrarian view: the AI investor base may be supporting valuation today, but the first hard readout—not the platform narrative—will determine whether this becomes a real rerating or just another pre-data de-rating cycle.

Key Decisions for Investors

• Tactically long SPCX only into the Nasdaq-100 inclusion window; target a 3-5 trading day hold and avoid chasing after the forced-buying bid is fully reflected. Risk/reward is flow-supported but unsustainable once passive demand clears.
• Fade the post-inclusion move in SPCX via a small short or put-spread overlay after the first 1-2 sessions of index buying, especially if volume spikes and then normalizes. Thesis is a classic event-driven mean reversion; invalidate if launch cadence or guidance improves materially.
• Short BLSH over a 1-3 month horizon, or pair it versus a cleaner crypto beta if available. The trade works if digital-asset volumes stay subdued and the market penalizes dilution/integration risk; cover if BTC and spot volumes reaccelerate decisively.
• No aggressive trade in GENB ahead of clinical data; treat it as a watch item, not a conviction long. If forced to express the view, size it as a small optionality position only on confirmed Phase 3 progress, with downside driven by biotech de-rating and financing risk.
• Use NDAQ as a modest relative-value beneficiary only if broader equity/IPO/volatility activity improves; otherwise keep it as a secondary proxy, not a primary idea. Upside is incremental and depends on market structure volumes, not a company-specific catalyst.